Summit backs Viroclinics Biosciences

Summit Partners managing director Thomas Tarnowski has joined the Viroclinics board of directors.

The investment will be used to fuel continued expansion of Viroclinics' services, capacity and international presence.

Summit Partners had not responded to a request for comment at the time of publication.

Previous funding
In January 2014, Gilde Healthcare Services acquired a majority stake in Viroclinics Biosciences from Erasmus University Medical Centre, allowing the institute to fully exit from the company. Gilde invested via its Gilde Healthcare Services I fund, a €50m vehicle launched in 2009.

In August 2017, Gilde sold the company to mid-cap buyout firm Parcom Capital Management. Viroclinics became fully owned by Parcom. In August 2019, Parcom exited Viroclinics.

Company
Founded in 2001 within the Erasmus Medical Center in Rotterdam, Viroclinics is a provider of specialised non-clinical and clinical services to the global virology therapeutics and vaccine development market. It specialises in influenza and other viral targets, including RSV and polio. The company employs 240 scientists, researchers and support staff.

People
Viroclinics Biosciences – Bob van Gemen (CEO).
Summit Partners – Thomas Tarnowski (managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Expansion
• Netherlands
• Summit Partners